Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations

Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations

Optimum management of patients with cancer during the COVID-19 pandemic has proved extremely challenging. Patients, clinicians and hospital authorities have had to balance the risks to patients of attending hospital, many of whom are especially vulnerable, with the risks of delaying or modifying can...

Bibliografske podrobnosti
Main Authors:	Brown, JE, Wood, SL, Confavreux, C, Abe, M, Weilbaecher, K, Hadji, P, Johnson, RW, Rhoades, JA, Edwards, CM, Croucher, PI, Juarez, P, El Badri, S, Ariaspinilla, G, D'Oronzo, S, Guise, TA, Van Poznak, C
Format:	Journal article
Jezik:	English
Izdano:	Elsevier 2021

Podobne knjige/članki

Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations
od: J.E. Brown, et al.
Izdano: (2021-08-01)

Metastatic bone disease: Pathogenesis and therapeutic options
od: Stella D'Oronzo, et al.
Izdano: (2019-04-01)

Tumor-host cell interactions in the bone disease of myeloma.
od: Fowler, J, et al.
Izdano: (2011)

Targeted RNA-seq signature of breast cancer (BC) circulating tumor cells (CTCs) correlates with the onset of bone-only metastases
od: Stella D'oronzo, et al.
Izdano: (2021-04-01)

Application of “omics” sciences to the prediction of bone metastases from breast cancer: State of the art
od: Marica Gentile, et al.
Izdano: (2021-02-01)

Combustion structures: is it a question of relationships?
od: Cosimo D’Oronzo
Izdano: (2019-12-01)

Osteoprotegerin and the development of myeloma bone disease
od: Croucher, P, et al.
Izdano: (2004)

Clinical disorders of bone resorption.
od: Russell, G, et al.
Izdano: (2001)

Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment.
od: Locklin, R, et al.
Izdano: (2007)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
od: Shipman, C, et al.
Izdano: (2002)

Advances in the molecular pharmacology of bone and cancer-related bone diseases
od: Edwards, CM, et al.
Izdano: (2021)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
od: Croucher, P, et al.
Izdano: (2003)

Bone marrow adipose tissue and cancer
od: Edwards, CM
Izdano: (2020)

Editorial: Cancer and bone metastasis, volume II
od: Chandi C. Mandal, et al.
Izdano: (2022-07-01)

Metabolism in the tumour-bone microenvironment
od: Whitburn, J, et al.
Izdano: (2021)

Editorial: Bone cell differentiation in health and disease, volume II
od: Chandi C. Mandal, et al.
Izdano: (2024-11-01)

Editorial - Cancer and Bone special issue
od: Edwards, CM, et al.
Izdano: (2022)

The role of bone marrow adipocytes in bone metastasis
od: Edwards, C, et al.
Izdano: (2016)

#23. Elucidating the role of bone marrow stiffness in estrogen signaling in metastatic breast cancer to the bone
od: Logan Northcutt, et al.
Izdano: (2024-04-01)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
od: De Leenheer, E, et al.
Izdano: (2004)

Psychotropic drugs and bone
od: R.W. Gasser, et al.
Izdano: (2024-12-01)

The Role of TGF-β in Bone Metastases
od: Trupti Trivedi, et al.
Izdano: (2021-11-01)

Morphogens and growth factor signalling in the myeloma bone-lining niche
od: Morris, EV, et al.
Izdano: (2021)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
od: De Leenheer, E, et al.
Izdano: (2002)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
od: Locklin, R, et al.
Izdano: (2005)

Bone marrow adipose tissue: a new player in cancer metastasis to bone
od: Morris, E, et al.
Izdano: (2016)

A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease.
od: Ayati, B, et al.
Izdano: (2010)

A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease
od: Webb Glenn F, et al.
Izdano: (2010-04-01)

Modeling the human bone–tumor niche: reducing and replacing the need for animal data
od: Rao, SR, et al.
Izdano: (2020)

#17. Evolution of epidemiology of bone metastasis in France: A rising issue
od: M Belhassen, et al.
Izdano: (2024-04-01)

The Bone Marrow Microenvironment in Multiple Myeloma
od: Edwards, C
Izdano: (2010)

#46. cAMP-mediated acid signaling regulates tumor-myeloid-bone cell crosstalk in the bone-tumor microenvironment
od: Kaylee O'Donnell, et al.
Izdano: (2024-04-01)

Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
od: Bauer M, et al.
Izdano: (2012-06-01)

Bone decalcification to assess programmed cell death ligand 1 expression in bone metastases of non-small cell lung cancers
od: Guillaume Pontarollo, et al.
Izdano: (2020-04-01)

Genetic models of bone disease using ENU mutagenesis
od: Brown, S, et al.
Izdano: (2009)

The role of bone marrow adipocytes in bone metastasis
od: Emma V. Morris, et al.
Izdano: (2016-09-01)

Statins and bone: myth or reality?
od: Edwards, C, et al.
Izdano: (2001)

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.
od: Edwards, C, et al.
Izdano: (2008)

#50. Investigating the role of EphA2 in breast cancer bone metastasis
od: Verra Ngwa, et al.
Izdano: (2024-04-01)

Wnt signaling: bone's defense against myeloma.
od: Edwards, C
Izdano: (2008)